The neglected tropical diseases (NTDs) diagnosis market is a crucial aspect of global health, focusing on diseases that disproportionately affect underserved populations in developing regions. These diseases, often underreported and underdiagnosed, present significant challenges to public health systems. However, recent technological advancements and global health initiatives have sparked hope for more efficient diagnostics. In this article, we will explore the neglected tropical diseases diagnosis market, its growth drivers, challenges, opportunities, and key players. Insights from the Persistence Market Research report provide a comprehensive outlook on market trends, segmentation, regional dynamics, and more.
Overview of the Market
The global market for neglected tropical diseases diagnosis is expected to grow significantly from US$ 7,600.0 million in 2025 to US$ 10,204.8 million by 2032. This growth represents a compound annual growth rate (CAGR) of approximately 4.3% from 2025 to 2032. The rise in market size is driven by the increasing need for effective diagnostics to combat a wide range of diseases that are prevalent in tropical regions. These diseases include soil-transmitted helminths, schistosomiasis, lymphatic filariasis, and more.
The key growth drivers behind this market’s expansion include increased funding for NTD programs, rising government initiatives focused on early detection, and technological advancements in diagnostic tools. Among the different diagnostic methods, conventional approaches such as microscopy still dominate due to their affordability and ease of use, particularly in low-resource settings. However, molecular diagnostics, offering greater sensitivity and field adaptability, are gaining momentum and are expected to lead the market in the coming years.
Key Highlights from the Report:
• Asia Pacific is predicted to hold a leading market share in 2025, driven by enhanced funding for NTD elimination programs.
• Soil-transmitted helminth infections will generate a market share of around 23.4% in 2025.
• Conventional diagnostic methods are projected to account for a significant share in 2025 due to their cost-effectiveness and simplicity.
• Multiplex assays are emerging as a key innovation, offering scalable solutions for diagnosing multiple NTDs simultaneously.
• Rising global elimination targets and increased funding are driving growth in the NTD diagnostics market.
• Governments worldwide are shifting from mass drug administration to precision diagnosis for more targeted interventions.
Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35377
Market Segmentation:
The neglected tropical diseases diagnosis market is segmented based on various factors such as product type, end-users, and diagnostic methods.
Product Type-Based Segmentation
Based on product type, the market is categorized into diagnostic kits and devices, reagents, and consumables. Diagnostic kits are the most commonly used products, offering quick and easy solutions for disease diagnosis. These kits are especially useful in remote and underserved areas where laboratory facilities are not readily available. The reagents segment is also significant, particularly in molecular diagnostics, as they enable more accurate detection of diseases. The increasing adoption of multiplex assays, which can test for multiple diseases simultaneously, is expected to boost the demand for reagents in the near future.
End-User Segmentation
The key end-users of NTD diagnostic tools include hospitals, research laboratories, diagnostic centers, and government health programs. Hospitals and diagnostic centers are the primary users of advanced molecular diagnostic tools. In contrast, research laboratories are focused on developing new diagnostic methods, while government programs focus on public health initiatives and large-scale screening campaigns. The government’s increasing role in funding NTD elimination programs and the rise of mobile diagnostics are shifting the market towards greater decentralization and community-based diagnostic approaches.
Regional Insights:
North America
Although neglected tropical diseases are more prevalent in developing countries, North America is witnessing increased attention to these diseases, particularly among immigrant populations. The U.S. and Canada have a growing recognition of the need for better NTD diagnostics, especially for diseases like Chagas and cysticercosis. However, access to diagnostic services remains a challenge in underserved communities. In 2023, the CDC identified a significant gap in Chagas disease diagnoses in the U.S., with less than 1% of suspected cases being formally diagnosed. Efforts are underway to enhance diagnostic infrastructure, with mobile outreach programs in Arizona and Texas providing testing for diseases like strongyloidiasis.
Middle East and Africa
The Middle East and Africa (MEA) region is expected to see substantial growth, particularly in Sub-Saharan Africa. The decentralized diagnostic approach, including community-based mobile units, has proven effective in detecting diseases like lymphatic filariasis and schistosomiasis in rural areas. Local innovations, such as solar-powered molecular diagnostic units in Senegal, are expected to play a key role in improving diagnostic sensitivity and availability. Countries like Ethiopia have also integrated point-of-care diagnostics into their public health strategies, further driving market growth.
Asia Pacific
Asia Pacific is predicted to dominate the neglected tropical diseases diagnosis market, with an estimated share of 32.7% in 2025. Countries such as Vietnam and Thailand are focusing on integrating NTD screening into their primary healthcare systems, offering a proactive approach to early disease detection. The use of rapid diagnostic tests (RDTs) in school health check-ups and mobile health units in rural areas is helping to expand screening coverage. Collaborative cross-border initiatives along the Mekong River basin are also fostering better disease surveillance and diagnostic harmonization.
Market Drivers:
National Programs for Early Detection
One of the most significant drivers of the NTD diagnosis market is the increasing number of government initiatives focused on early disease detection and mapping. National programs, such as India’s Kala-Azar elimination campaign, have resulted in increased case detection and targeted interventions. These programs leverage mobile diagnostic units and Rapid Diagnostic Tests (RDTs), which are proving successful in regions where traditional healthcare infrastructure is limited.
Technological Advancements in Diagnostics
Technological innovation is another key factor driving market growth. Advances in molecular diagnostics, such as PCR and Loop-Mediated Isothermal Amplification (LAMP), have enhanced the sensitivity of diagnostic tools, enabling earlier and more accurate detection of NTDs. A notable example is the handheld PCR device developed by the London School of Hygiene & Tropical Medicine, which has shown to improve early case detection of Leishmania donovani by 40% in field trials.
Rising Funding for NTD Elimination Programs
Increased international and governmental funding for NTD control programs is fueling market growth. Organizations like the World Health Organization (WHO) and the Global Health Innovative Technology Fund (GHIT) are investing heavily in NTD diagnostics, developing affordable and effective diagnostic tools for rural and underserved populations. These investments are particularly important in endemic countries where resources are scarce.
Market Restraints
Limited Resources and Conflict
Resource constraints remain a significant challenge in the NTD diagnostics market. In conflict zones like Sudan, laboratory facilities are often repurposed for emergency care, halting NTD diagnostic efforts. Moreover, shortages of trained healthcare personnel exacerbate this issue, limiting the ability to implement and scale diagnostic programs. In rural areas, the lack of skilled personnel to conduct even basic diagnostic tests, such as thick smear or Kato-Katz procedures, hinders the effectiveness of NTD control programs.
Economic and Political Barriers
Political instability and economic constraints also pose significant barriers to progress. Many endemic countries face competing public health priorities, which often dilute resources allocated for NTD control. Additionally, the lack of regulatory support for new diagnostic tools can delay their adoption and hinder market growth.
Market Opportunities
Innovation in AI and Mobile Diagnostics
The integration of Artificial Intelligence (AI) and mobile diagnostic tools presents significant opportunities for the NTD diagnosis market. AI-powered diagnostic applications, such as the one developed in Tanzania for schistosomiasis, enable community health workers to conduct accurate screenings without specialized training. These innovations are expected to increase diagnostic coverage, especially in remote areas with limited access to healthcare infrastructure.
Development of Field-Ready Diagnostic Tools
Another promising opportunity lies in the development of field-ready diagnostic tools. Portable and battery-operated devices, such as the PCR device for Leishmania donovani detection, offer high sensitivity in low-resource settings. These tools provide healthcare workers with a means of performing accurate diagnostics in remote locations, helping to bridge the gap between laboratory-based and field diagnostics.
Reasons to Buy the Report:
• Gain a comprehensive understanding of the neglected tropical diseases diagnosis market dynamics.
• Understand the key market drivers and challenges affecting the growth of the industry.
• Discover the latest technological advancements in NTD diagnostics.
• Assess the market opportunities emerging from innovative diagnostic methods.
• Identify leading players in the market and their strategies for growth.
Frequently Asked Questions (FAQs):
• How Big is the Neglected Tropical Diseases Diagnosis Market?
• Who are the Key Players in the Global Market for Neglected Tropical Diseases Diagnosis?
• What is the Projected Growth Rate of the Market?
• What is the Market Forecast for 2032?
• Which Region is Estimated to Dominate the Industry through the Forecast Period?
Key Players:
• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Genome Diagnostics Pvt. Ltd.
• InBios International, Inc.
• ZeptoMetrix
• Oscar Medicare Pvt Ltd.
• Coris BioConcept
• Omega Diagnostics Group PLC
• DiaSys Diagnostic Systems GmbH
Recent Developments:
In March 2025, the GHIT Fund announced an investment of US$ 11.4 million in projects focused on neglected tropical diseases and schistosomiasis diagnostics. In December 2024, the GHIT Fund and WHO signed a memorandum of understanding to extend their collaboration, promoting affordable diagnostics for neglected tropical diseases.
Conclusion:
The neglected tropical diseases diagnosis market is at a pivotal point, with significant growth expected in the coming years. As governments, international organizations, and the private sector increase their focus on innovative diagnostic tools, the market is poised for a transformative shift. With the right investments in technology and infrastructure, the world can make substantial progress in controlling and eventually eliminating neglected tropical diseases.
Read Related Reports:
